Altimmune announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to its clinical program investigating pemvidutide for the treatment of NASH. “The FDA’s decision was informed by the results of Altimmune’s studies including its Phase 1b randomized, placebo-controlled study of pemvidutide in subjects with non-alcoholic fatty liver disease, which showed class-leading relative reductions in liver fat and non-invasive markers of hepatic inflammation and a favorable safety and tolerability profile,” said Vipin Garg, Ph.D., President and CEO of Altimmune. “The Fast Track designation reflects Altimmune’s commitment to patients with NASH and efforts to find safe and effective treatments for this condition.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALT:
- Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
- Altimmune to Participate at Two Upcoming Investor Conferences
- Biotech Alert: Searches spiking for these stocks today
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
- Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight